89bio logo

89bio

Developing and commercializing innovative therapies for the treatment of liver and cardio-metabolic diseases

123 employees · est. 2018 · San Francisco, United States

VS
CORXEL Pharmaceuticals logo

CORXEL Pharmaceuticals

Our mission is to develop innovative cardiometabolic therapies globally.

40 employees · est. 2019 · Shanghai, China

89bio is the older company (2018 vs 2019); 89bio is the larger of the two.

Side-by-Side Comparison

89bio CORXEL Pharmaceuticals
Founded
2018 older 2019
Headquarters
San Francisco, United States Shanghai, China
Employees
123 larger 40
Industry
Biopharma, Biotechnology, Pharmaceutical Biotechnology, Health Care
Funding Stage
Post Ipo Equity Series D
Total Funding
$773.20M $162.00M
Funding Rounds
7 2
Services
Not tracked yet Not tracked yet
Target Customers
Not tracked yet Not tracked yet
Taxonomy
Biopharmaceutical Company, Clinical-stage, FGF21 Analog, NASH Treatment, SHTG Treatment, Liver Diseases, Cardio-metabolic Diseases, Innovative Therapies, Phase 2 Trial, Patient-centric, Ethical Standards, Scientific Advancement, San Francisco, Herzliya, Israel Biopharmaceutical, Innovation, Therapeutics, Clinical Development, Ophthalmology, Cardiovascular, Global Partnerships, Patient-Centric, Unmet Medical Needs, China Healthcare, RTW Investments
Website
89bio.com jixing.com
89bio logo

About 89bio

89bio 89bio is a clinical-stage biopharmaceutical company with a focus on developing and commercializing innovative therapies for the treatment of liver and cardio-metabolic diseases. Their lead product candidate, BIO89-100, is an engineered glycoPEGylated analog of FGF21 designed for the treatment...

CORXEL Pharmaceuticals logo

About CORXEL Pharmaceuticals

Jixing Pharmaceuticals, founded in 2019, is a biopharmaceutical company based in Shanghai, China. The company's slogan, "Our mission is to develop novel therapeutics, bridging the innovation gap for patients in China," reflects its dedication to bringing innovative science and medicines to underserv...

We will tell you when either one moves

BounceWatch watches 89bio and CORXEL Pharmaceuticals for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at 89bio and CORXEL Pharmaceuticals — by email.

Frequently Asked Questions

89bio — Developing and commercializing innovative therapies for the treatment of liver and cardio-metabolic diseases. CORXEL Pharmaceuticals — Our mission is to develop innovative cardiometabolic therapies globally.. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
89bio has raised $773.20M while CORXEL Pharmaceuticals has raised $162.00M.
89bio and CORXEL Pharmaceuticals operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare 89bio with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at 89bio on 9 Jun 2026, and CORXEL Pharmaceuticals on 12 Sep 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy